Portugal has steadily grown its clinical research profile over the past decade, establishing itself as a credible and cost-effective option for sponsors seeking Southern European diversity in multinational programmes. With a population of approximately 10.3 million and an increasingly well-organised national research infrastructure, Portugal offers competitive per-patient costs, experienced investigators at its university hospital networks, and full integration with the EU Clinical Trials Regulation (EU CTR, Regulation EU 536/2014) via CTIS.
Portugal’s principal strengths lie in oncology, hepatology, infectious diseases, cardiovascular medicine, and nephrology. The national cancer institutes (IPO Lisboa and IPO Porto) are the country’s most active oncology trial sites, while Hospital de Santa Maria and Hospital de São João provide broad therapeutic coverage. The research community is Portuguese-speaking, and patient-facing documentation must be prepared in Portuguese.
Historically, Portugal faced criticism for administrative slowness in clinical trial processing. Under the EU CTR framework, timelines have improved, though they remain somewhat longer than the fastest EU countries such as Denmark or Sweden. Sponsors should plan for realistic timelines and invest in early site engagement to compress the post-approval start-up phase.
| Metric | Portugal |
| Competent Authority | INFARMED (Autoridade Nacional do Medicamento) |
| Ethics Review | CEIC (Comissão de Ética para a Investigação Clínica) |
| Approval Timeline | ~45–60 days |
| Population | ~10.3 million |
| Strengths | Oncology, hepatology, infectious diseases, cardiovascular, nephrology |
Portugal occupies a useful position in the European clinical trial landscape: more affordable than Spain for comparable quality at many sites, and offering a distinct patient demographic that adds scientific value to multinational programmes. Key reasons sponsors include Portugal:
Portugal has fewer major trial sites than Spain and a smaller overall patient population. It is most effective when used alongside one or two other Southern European countries rather than as the sole Southern European site. Sponsors should be realistic about the number of patients that Portuguese sites can contribute per study.
Portugal fully implements the EU Clinical Trials Regulation (EU CTR, Regulation EU 536/2014) and submits all interventional clinical trial applications via CTIS. The national competent authority is INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde, I.P.), which handles the scientific and safety assessment.
The ethics review is conducted by the CEIC (Comissão de Ética para a Investigação Clínica), Portugal’s national clinical research ethics committee. The CEIC is a centralised body, meaning there is one national ethics review for all Portuguese sites rather than a fragmented multi-committee system. This is a structural advantage for sponsors running multi-site studies within Portugal.
INFARMED and the CEIC conduct their reviews in parallel under the EU CTR framework. Portugal can act as either the Reporting Member State (RMS) or a Member State Concerned (MSC) in multi-country submissions. For non-interventional and observational studies, separate Portuguese legislation applies and sponsors should seek specific guidance from INFARMED.
Portugal has historically been among the slower EU countries for clinical trial approval, though performance has improved under the EU CTR. Sponsors should plan for the following indicative timelines:
| Step | Estimated Timeline |
|---|---|
| CTIS submission and validation | 1–7 working days |
| INFARMED Part I assessment | ~45–60 days |
| CEIC Part II assessment | ~45–60 days (parallel) |
| RFI response period (if applicable) | 12–31 days (clock stopped) |
| Site contract and budget negotiation | 6–16 weeks (site dependent) |
| Estimated total from submission to first patient | ~4–7 months |
The national cancer institutes (IPO Lisboa, IPO Porto) have dedicated research offices and typically move through contracting more efficiently than general university hospitals. Sponsors with pre-established relationships at Portuguese sites can compress these timelines meaningfully.
Portugal’s clinical trial activity is concentrated in Lisbon and Porto. Key institutions include:
Coimbra’s Centro Hospitalar e Universitário de Coimbra (CHUC) is also active in certain specialties. Outside the Lisbon–Porto axis, trial activity is limited and sponsors should plan primarily around these two cities.
Portugal’s patient pool is adequate for contribution to multinational trials but is insufficient to carry large studies independently. The Serviço Nacional de Saúde (SNS, the national health service) provides relatively centralised care, meaning that referral networks within the major hospital centres are well-developed and eligible patients tend to be funnelled to the specialist institutions that run trials.
For oncology and hepatology in particular, Portugal’s trial sites see a reasonable volume of treatment-naive patients presenting through the public health system. The country’s relatively high prevalence of hepatitis C historically, and ongoing research activity in chronic liver disease, makes Portugal a strong option for hepatology programmes. For rare diseases, the national referral system concentrates patients at specialist centres, aiding identification.
Start-up in Portugal has historically been one of the longer processes in Southern Europe. Administrative processes within hospitals, including internal legal and financial committee reviews, can add time beyond the regulatory approval. The following reflects typical ranges for well-managed programmes:
| Activity | Estimated Duration |
|---|---|
| Regulatory and ethics approval (CTIS) | 45–60 days |
| Site contract and budget negotiation | 8–16 weeks |
| Site initiation visit and staff training | 2–4 weeks |
| Local hospital administrative approvals | 4–8 weeks |
| First patient screened | ~5–8 months from submission |
Progress has been made under CTIS, and sponsors who invest in early site engagement and use a local CRO or site management partner typically achieve faster start-up than those relying solely on central coordination.
Portugal is one of the more cost-competitive Western European countries for clinical research. Investigator fees, research nurse salaries, and hospital overhead charges are generally lower than in Spain, France, or Germany. Per-patient costs for a Phase II oncology study typically range from €14,000 to €32,000, making Portugal meaningfully cheaper than most Western European comparators.
Translation costs for Portuguese-language patient documents should be budgeted, as should local regulatory fees to INFARMED and CEIC. The SNS covers standard-of-care elements for trial participants in most cases, reducing the per-patient charge to sponsors for hospitalisation and routine procedures.
Portugal is most valuable when sponsors are building out a Southern European presence and want a cost-effective complement to Spain or Italy. It is a strong choice when:
Portugal is less suitable as a standalone country for trials needing rapid start-up or very large patient volumes. Its administrative processes, while improving, remain slower than Northern European countries.
APICES provides end-to-end CRO services for clinical trials in Portugal, including CTIS regulatory submissions, INFARMED and CEIC liaison, site identification, feasibility assessment, and site management. We have working relationships with Portugal’s principal trial sites in Lisbon and Porto and understand the administrative processes that typically extend start-up timelines.
Our Portugal-specific services include Portuguese-language document preparation and review, local regulatory monitoring, and coordination with hospital research offices to compress contracting timelines. For sponsors incorporating Portugal into a European programme, we provide integrated oversight across all participating countries via CTIS.
How long does clinical trial approval take in Portugal?
Under the EU CTR, all interventional clinical trial applications in Portugal are submitted via CTIS. INFARMED conducts the Part I scientific and safety assessment while the CEIC conducts the Part II ethical review in parallel. For a well-prepared and complete dossier, the combined regulatory and ethics decision typically falls within 45–60 days from validation. Portugal has historically been one of the slower EU countries to process applications, but performance has improved since the transition to CTIS. Requests for information (RFIs) from either INFARMED or the CEIC will pause the statutory clock, and sponsors should ensure dossiers are thorough to minimise RFI risk.
Who is the competent authority for clinical trials in Portugal?
INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde, I.P.) is Portugal’s national competent authority for medicines and clinical trials. The CEIC (Comissão de Ética para a Investigação Clínica) is Portugal’s sole national clinical research ethics committee, responsible for the ethical review of all interventional clinical trials. The CEIC’s centralised model means a single ethics review covers all Portuguese sites, which is a genuine administrative advantage for multi-site programmes.
What language must patient documents be in for Portuguese clinical trials?
All patient-facing documents must be prepared in Portuguese. This includes informed consent forms (ICFs), patient information sheets, any patient diaries or questionnaires, and recruitment materials. The CEIC reviews these documents as part of the Part II assessment and expects clear, plain-language Portuguese. Research staff and investigators at major Portuguese trial sites (IPO Lisboa, Hospital de São João, Hospital de Santa Maria) are accustomed to working with international sponsors and communicate readily in English for operational and scientific matters.
What are the main oncology trial sites in Portugal?
IPO Lisboa (Instituto Português de Oncologia de Lisboa) and IPO Porto (Instituto Português de Oncologia do Porto) are the country’s most active dedicated oncology trial sites and should be the first consideration for most oncology programmes. Hospital de São João (CHUP) in Porto and Hospital de Santa Maria (CHLN) in Lisbon also run significant oncology programmes across multiple tumour types. Centro Hospitalar e Universitário de Coimbra (CHUC) is active in some haematology and solid tumour indications.
How does Portugal compare to Spain for clinical trials?
Portugal offers meaningfully lower per-patient costs than Spain for comparable therapeutic areas, and its centralised national ethics review through the CEIC is administratively simpler than Spain’s fragmented multi-committee system. However, Portugal has a substantially smaller patient population (10.3 million versus ~47 million in Spain) and fewer trial sites. Spain offers greater enrolment capacity and a wider geographic spread of sites. Many sponsors use both countries together to gain Southern European diversity; Portugal adds value as the lower-cost, specialist complement to Spain’s larger enrolment network.
What does a Phase II oncology trial cost per patient in Portugal?
Per-patient costs for a Phase II oncology trial in Portugal typically range from €14,000 to €32,000 depending on protocol complexity, the number and type of assessments, site-specific overheads, and investigator fees. Portugal is one of the more cost-competitive Western European countries for clinical research. The Serviço Nacional de Saúde (SNS) covers standard-of-care costs for trial participants in most cases, which reduces the per-patient charge to sponsors. Sponsors should budget separately for INFARMED and CEIC fees and Portuguese-language document preparation.
Get the latest clinical insights delivered to your feed or inbox!
Key Takeaways: First-in-human trials in the EU are governed by Regulation (EU) No 536/2014 and the EMA’s first-in-human guideline (EMEA/CHMP/SWP/28367/07 Rev 1). Sponsors must submit a complete Clinical Trial Application via the CTIS portal and obtain both Part I...
Key Takeaways: Phase I dose escalation design in the EU is governed by ICH E8(R1), EMA first-in-human guidance (EMA/CHMP/SWP/28367/07 Rev.1), and EU Clinical Trial Regulation 536/2014 via CTIS. The classical 3+3 design is increasingly replaced by model-based...
EU MDR clinical investigation requirements have fundamentally changed how Medtech sponsors plan and execute device studies in Europe. Regulation (EU) 2017/745 replaced the clinical investigation provisions of Directive 93/42/EEC (MDD) and introduced a more stringent, harmonised framework across all 27 EU member states. For sponsors running investigations in Spain, Germany, France, the Netherlands, or any other member state, understanding which pathway applies to their study is the single most consequential regulatory decision before CIP submission.
